Periostat

Rocky Mountain Spotted Fever, Acinetobacter Infections, Ureaplasma Infections + 61 more
Treatment
93 FDA approvals
18 Active Studies for Periostat

What is Periostat

DoxycyclineThe Generic name of this drug
Treatment SummaryDoxycycline is an antibiotic used to treat a wide range of bacterial infections. It is a synthetically derived version of the tetracycline family of antibiotics, with fewer side effects than the first-generation tetracyclines. Its effectiveness against specific bacteria can be determined through antibiotic susceptibility testing.
Vibramycin Hyclateis the brand name
image of different drug pills on a surface
Periostat Overview & Background
Brand Name
Generic Name
First FDA Approval
How many FDA approvals?
Vibramycin Hyclate
Doxycycline
1967
728

Approved as Treatment by the FDA

Doxycycline, otherwise known as Vibramycin Hyclate, is approved by the FDA for 93 uses such as Chlamydia Infections and Listeria infection .
Chlamydia Infections
Listeria infection
Primary Syphilis
Bacteriological Techniques
Staphylococcus (S.) Aureus Infection
Anal chlamydia infection
Upper Respiratory Tract Infection
Streptococcus Pneumoniae Infections
Clostridium difficile Infection
Genus Chlamydia
Rickettsialpox
Cholera (Disorder)
Communicable Diseases
Intestinal Amebiasis
Relapsing fever caused by Borrelia recurrentis
Actinomycosis
Campylobacter Infections
Secondary Syphilis
Necrotizing ulcerative gingivostomatitis
Mycoplasma Pneumoniae
Inclusion conjunctivitis
Klebsiella Infections
Tick-borne fever
Severe Acne
Chlamydia Infections
Campylobacter Infection
Urethritis
Urinary Tract Infections
Plasmodium Infections
Skin Infections
Chlamydia trachomatis
Typhus, Endemic Flea-Borne
Communicable Diseases
Chlamydial cervicitis
Chlamydial Urethritis
Haemophilus Influenzae Infections
Calymmatobacterium granulomatis
Lymphogranuloma Venereum
Dysentery, Bacillary
Fever
Ureaplasma urethritis
Gonorrhea
Bartonella Infections
Acne Vulgaris
Q Fever
Acinetobacter Infections
Ureaplasma Infections
Communicable Diseases
Uterine Cervicitis
Tularemia
Typhus infections
Epididymo-orchitis gonococcal
Trachoma
Neisseria Gonorrhoeae Infection
Rocky Mountain Spotted Fever
Bartonella bacilliformis infections
Malaria
Bacterial Infection caused by Enterobacter aerogenes
Relapsing Fever
Yaws
Chancroid
Amebic colitis
Brucellosis
Used to treat Brucellosis in combination with Streptomycin
Recurrent Upper and Lower Respiratory Tract Infections (RTIs)
Plague
Chlamydia trachomatis
Cat-Scratch Disease
Shigella Infection
inhaled anthrax caused by Bacillus anthracis
Pneumococcal Infections
Clostridium Infections
Common Cold
Brucellosis
Used to treat Brucellosis in combination with Streptomycin
Trachoma
Plague
Urethritis
Acinetobacter Infections
Yersinia pestis
Psittacosis
Chlamydia psitacci infection
Ureaplasma Infections
Infection Due to Escherichia Coli
Trachoma inclusion conjunctivitis
Listeriosis
Yaws
Relapsing Fever
Vibrio Cholerae Infection
Disease
Haemophilus ducreyi infection
Tularemia
prophylaxis of Malaria
Respiratory Tract Infections
Granuloma Inguinale

Effectiveness

How Periostat Affects PatientsDoxycycline and other tetracyclines stop bacteria from growing or keep them in a stationary state. They work against both gram-positive and gram-negative bacteria, and these bacteria are often resistant to tetracyclines. Doxycycline is a lipophilic drug, which means it can penetrate cells and has a wide range of effects, such as being antibacterial, antiparasitic, and anti-inflammatory. It has been used to treat skin conditions such as bullous dermatoses and rosacea.
How Periostat works in the bodyDoxycycline stops bacteria from making necessary proteins that allow them to survive and function. It does this by blocking the binding of amino acids to ribosomes, which are responsible for making proteins. Doxycycline also blocks inflammation by preventing calcium-dependent cells from forming and stopping lymphocytes from growing. It also stops an enzyme that produces a molecule that causes inflammation.

When to interrupt dosage

The prescribed dose of Periostat is reliant upon the diagnosed condition, such as Urethritis, Chlamydia trachomatis and Respiratory Tract Infections. The measure of dosage differs, in accordance with the method of delivery (e.g. Capsule or Syrup - Oral) featured in the table underneath.
Condition
Dosage
Administration
Acinetobacter Infections
10.0 mg/mL, , 75.0 mg, 100.0 mg, 150.0 mg, 50.0 mg, 200.0 mg, 20.0 mg, 1.0 mg/mg, 40.0 mg, 5.0 mg/mg, 7.5 mg/mg, 25.0 mg/mL, 50.0 mg/mL, 120.0 mg, 60.0 mg, 0.1 mg/mg, 5.0 mg/mL, 8.8 %, 20.0 mg/mL, 0.75 mg/mg, 0.5 mg/mg, 80.0 mg
, Intravenous, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous, Oral, Tablet, delayed release, Tablet, delayed release - Oral, Capsule, Capsule - Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, Tablet - Oral, Tablet, coated, Tablet, coated - Oral, Capsule, gelatin coated, Capsule, gelatin coated - Oral, Capsule, delayed release pellets, Capsule, delayed release pellets - Oral, Kit - Oral, Kit, Capsule, extended release, Capsule, extended release - Oral, Powder - Intravenous, Powder, for suspension, Powder, for suspension - Oral, Syrup - Oral, Syrup, For suspension - Oral, Gel - Oral, Suspension - Oral, Capsule, Delayed Release - Oral, Capsule, Delayed Release, Powder, For suspension, Oral; Topical, Capsule - Oral; Topical, Injection, powder, for solution, Injection, powder, for solution - Intravenous
Ureaplasma Infections
10.0 mg/mL, , 75.0 mg, 100.0 mg, 150.0 mg, 50.0 mg, 200.0 mg, 20.0 mg, 1.0 mg/mg, 40.0 mg, 5.0 mg/mg, 7.5 mg/mg, 25.0 mg/mL, 50.0 mg/mL, 120.0 mg, 60.0 mg, 0.1 mg/mg, 5.0 mg/mL, 8.8 %, 20.0 mg/mL, 0.75 mg/mg, 0.5 mg/mg, 80.0 mg
, Intravenous, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous, Oral, Tablet, delayed release, Tablet, delayed release - Oral, Capsule, Capsule - Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, Tablet - Oral, Tablet, coated, Tablet, coated - Oral, Capsule, gelatin coated, Capsule, gelatin coated - Oral, Capsule, delayed release pellets, Capsule, delayed release pellets - Oral, Kit - Oral, Kit, Capsule, extended release, Capsule, extended release - Oral, Powder - Intravenous, Powder, for suspension, Powder, for suspension - Oral, Syrup - Oral, Syrup, For suspension - Oral, Gel - Oral, Suspension - Oral, Capsule, Delayed Release - Oral, Capsule, Delayed Release, Powder, For suspension, Oral; Topical, Capsule - Oral; Topical, Injection, powder, for solution, Injection, powder, for solution - Intravenous
Psittacosis
10.0 mg/mL, , 75.0 mg, 100.0 mg, 150.0 mg, 50.0 mg, 200.0 mg, 20.0 mg, 1.0 mg/mg, 40.0 mg, 5.0 mg/mg, 7.5 mg/mg, 25.0 mg/mL, 50.0 mg/mL, 120.0 mg, 60.0 mg, 0.1 mg/mg, 5.0 mg/mL, 8.8 %, 20.0 mg/mL, 0.75 mg/mg, 0.5 mg/mg, 80.0 mg
, Intravenous, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous, Oral, Tablet, delayed release, Tablet, delayed release - Oral, Capsule, Capsule - Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, Tablet - Oral, Tablet, coated, Tablet, coated - Oral, Capsule, gelatin coated, Capsule, gelatin coated - Oral, Capsule, delayed release pellets, Capsule, delayed release pellets - Oral, Kit - Oral, Kit, Capsule, extended release, Capsule, extended release - Oral, Powder - Intravenous, Powder, for suspension, Powder, for suspension - Oral, Syrup - Oral, Syrup, For suspension - Oral, Gel - Oral, Suspension - Oral, Capsule, Delayed Release - Oral, Capsule, Delayed Release, Powder, For suspension, Oral; Topical, Capsule - Oral; Topical, Injection, powder, for solution, Injection, powder, for solution - Intravenous
Cat-Scratch Disease
10.0 mg/mL, , 75.0 mg, 100.0 mg, 150.0 mg, 50.0 mg, 200.0 mg, 20.0 mg, 1.0 mg/mg, 40.0 mg, 5.0 mg/mg, 7.5 mg/mg, 25.0 mg/mL, 50.0 mg/mL, 120.0 mg, 60.0 mg, 0.1 mg/mg, 5.0 mg/mL, 8.8 %, 20.0 mg/mL, 0.75 mg/mg, 0.5 mg/mg, 80.0 mg
, Intravenous, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous, Oral, Tablet, delayed release, Tablet, delayed release - Oral, Capsule, Capsule - Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, Tablet - Oral, Tablet, coated, Tablet, coated - Oral, Capsule, gelatin coated, Capsule, gelatin coated - Oral, Capsule, delayed release pellets, Capsule, delayed release pellets - Oral, Kit - Oral, Kit, Capsule, extended release, Capsule, extended release - Oral, Powder - Intravenous, Powder, for suspension, Powder, for suspension - Oral, Syrup - Oral, Syrup, For suspension - Oral, Gel - Oral, Suspension - Oral, Capsule, Delayed Release - Oral, Capsule, Delayed Release, Powder, For suspension, Oral; Topical, Capsule - Oral; Topical, Injection, powder, for solution, Injection, powder, for solution - Intravenous
Lymphogranuloma Venereum
10.0 mg/mL, , 75.0 mg, 100.0 mg, 150.0 mg, 50.0 mg, 200.0 mg, 20.0 mg, 1.0 mg/mg, 40.0 mg, 5.0 mg/mg, 7.5 mg/mg, 25.0 mg/mL, 50.0 mg/mL, 120.0 mg, 60.0 mg, 0.1 mg/mg, 5.0 mg/mL, 8.8 %, 20.0 mg/mL, 0.75 mg/mg, 0.5 mg/mg, 80.0 mg
, Intravenous, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous, Oral, Tablet, delayed release, Tablet, delayed release - Oral, Capsule, Capsule - Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, Tablet - Oral, Tablet, coated, Tablet, coated - Oral, Capsule, gelatin coated, Capsule, gelatin coated - Oral, Capsule, delayed release pellets, Capsule, delayed release pellets - Oral, Kit - Oral, Kit, Capsule, extended release, Capsule, extended release - Oral, Powder - Intravenous, Powder, for suspension, Powder, for suspension - Oral, Syrup - Oral, Syrup, For suspension - Oral, Gel - Oral, Suspension - Oral, Capsule, Delayed Release - Oral, Capsule, Delayed Release, Powder, For suspension, Oral; Topical, Capsule - Oral; Topical, Injection, powder, for solution, Injection, powder, for solution - Intravenous
Brucellosis
10.0 mg/mL, , 75.0 mg, 100.0 mg, 150.0 mg, 50.0 mg, 200.0 mg, 20.0 mg, 1.0 mg/mg, 40.0 mg, 5.0 mg/mg, 7.5 mg/mg, 25.0 mg/mL, 50.0 mg/mL, 120.0 mg, 60.0 mg, 0.1 mg/mg, 5.0 mg/mL, 8.8 %, 20.0 mg/mL, 0.75 mg/mg, 0.5 mg/mg, 80.0 mg
, Intravenous, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous, Oral, Tablet, delayed release, Tablet, delayed release - Oral, Capsule, Capsule - Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, Tablet - Oral, Tablet, coated, Tablet, coated - Oral, Capsule, gelatin coated, Capsule, gelatin coated - Oral, Capsule, delayed release pellets, Capsule, delayed release pellets - Oral, Kit - Oral, Kit, Capsule, extended release, Capsule, extended release - Oral, Powder - Intravenous, Powder, for suspension, Powder, for suspension - Oral, Syrup - Oral, Syrup, For suspension - Oral, Gel - Oral, Suspension - Oral, Capsule, Delayed Release - Oral, Capsule, Delayed Release, Powder, For suspension, Oral; Topical, Capsule - Oral; Topical, Injection, powder, for solution, Injection, powder, for solution - Intravenous
Chlamydia Infections
10.0 mg/mL, , 75.0 mg, 100.0 mg, 150.0 mg, 50.0 mg, 200.0 mg, 20.0 mg, 1.0 mg/mg, 40.0 mg, 5.0 mg/mg, 7.5 mg/mg, 25.0 mg/mL, 50.0 mg/mL, 120.0 mg, 60.0 mg, 0.1 mg/mg, 5.0 mg/mL, 8.8 %, 20.0 mg/mL, 0.75 mg/mg, 0.5 mg/mg, 80.0 mg
, Intravenous, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous, Oral, Tablet, delayed release, Tablet, delayed release - Oral, Capsule, Capsule - Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, Tablet - Oral, Tablet, coated, Tablet, coated - Oral, Capsule, gelatin coated, Capsule, gelatin coated - Oral, Capsule, delayed release pellets, Capsule, delayed release pellets - Oral, Kit - Oral, Kit, Capsule, extended release, Capsule, extended release - Oral, Powder - Intravenous, Powder, for suspension, Powder, for suspension - Oral, Syrup - Oral, Syrup, For suspension - Oral, Gel - Oral, Suspension - Oral, Capsule, Delayed Release - Oral, Capsule, Delayed Release, Powder, For suspension, Oral; Topical, Capsule - Oral; Topical, Injection, powder, for solution, Injection, powder, for solution - Intravenous
Actinomycosis
10.0 mg/mL, , 75.0 mg, 100.0 mg, 150.0 mg, 50.0 mg, 200.0 mg, 20.0 mg, 1.0 mg/mg, 40.0 mg, 5.0 mg/mg, 7.5 mg/mg, 25.0 mg/mL, 50.0 mg/mL, 120.0 mg, 60.0 mg, 0.1 mg/mg, 5.0 mg/mL, 8.8 %, 20.0 mg/mL, 0.75 mg/mg, 0.5 mg/mg, 80.0 mg
, Intravenous, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous, Oral, Tablet, delayed release, Tablet, delayed release - Oral, Capsule, Capsule - Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, Tablet - Oral, Tablet, coated, Tablet, coated - Oral, Capsule, gelatin coated, Capsule, gelatin coated - Oral, Capsule, delayed release pellets, Capsule, delayed release pellets - Oral, Kit - Oral, Kit, Capsule, extended release, Capsule, extended release - Oral, Powder - Intravenous, Powder, for suspension, Powder, for suspension - Oral, Syrup - Oral, Syrup, For suspension - Oral, Gel - Oral, Suspension - Oral, Capsule, Delayed Release - Oral, Capsule, Delayed Release, Powder, For suspension, Oral; Topical, Capsule - Oral; Topical, Injection, powder, for solution, Injection, powder, for solution - Intravenous
Inclusion conjunctivitis
10.0 mg/mL, , 75.0 mg, 100.0 mg, 150.0 mg, 50.0 mg, 200.0 mg, 20.0 mg, 1.0 mg/mg, 40.0 mg, 5.0 mg/mg, 7.5 mg/mg, 25.0 mg/mL, 50.0 mg/mL, 120.0 mg, 60.0 mg, 0.1 mg/mg, 5.0 mg/mL, 8.8 %, 20.0 mg/mL, 0.75 mg/mg, 0.5 mg/mg, 80.0 mg
, Intravenous, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous, Oral, Tablet, delayed release, Tablet, delayed release - Oral, Capsule, Capsule - Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, Tablet - Oral, Tablet, coated, Tablet, coated - Oral, Capsule, gelatin coated, Capsule, gelatin coated - Oral, Capsule, delayed release pellets, Capsule, delayed release pellets - Oral, Kit - Oral, Kit, Capsule, extended release, Capsule, extended release - Oral, Powder - Intravenous, Powder, for suspension, Powder, for suspension - Oral, Syrup - Oral, Syrup, For suspension - Oral, Gel - Oral, Suspension - Oral, Capsule, Delayed Release - Oral, Capsule, Delayed Release, Powder, For suspension, Oral; Topical, Capsule - Oral; Topical, Injection, powder, for solution, Injection, powder, for solution - Intravenous
prophylaxis of Malaria
10.0 mg/mL, , 75.0 mg, 100.0 mg, 150.0 mg, 50.0 mg, 200.0 mg, 20.0 mg, 1.0 mg/mg, 40.0 mg, 5.0 mg/mg, 7.5 mg/mg, 25.0 mg/mL, 50.0 mg/mL, 120.0 mg, 60.0 mg, 0.1 mg/mg, 5.0 mg/mL, 8.8 %, 20.0 mg/mL, 0.75 mg/mg, 0.5 mg/mg, 80.0 mg
, Intravenous, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous, Oral, Tablet, delayed release, Tablet, delayed release - Oral, Capsule, Capsule - Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, Tablet - Oral, Tablet, coated, Tablet, coated - Oral, Capsule, gelatin coated, Capsule, gelatin coated - Oral, Capsule, delayed release pellets, Capsule, delayed release pellets - Oral, Kit - Oral, Kit, Capsule, extended release, Capsule, extended release - Oral, Powder - Intravenous, Powder, for suspension, Powder, for suspension - Oral, Syrup - Oral, Syrup, For suspension - Oral, Gel - Oral, Suspension - Oral, Capsule, Delayed Release - Oral, Capsule, Delayed Release, Powder, For suspension, Oral; Topical, Capsule - Oral; Topical, Injection, powder, for solution, Injection, powder, for solution - Intravenous
Relapsing Fever
10.0 mg/mL, , 75.0 mg, 100.0 mg, 150.0 mg, 50.0 mg, 200.0 mg, 20.0 mg, 1.0 mg/mg, 40.0 mg, 5.0 mg/mg, 7.5 mg/mg, 25.0 mg/mL, 50.0 mg/mL, 120.0 mg, 60.0 mg, 0.1 mg/mg, 5.0 mg/mL, 8.8 %, 20.0 mg/mL, 0.75 mg/mg, 0.5 mg/mg, 80.0 mg
, Intravenous, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous, Oral, Tablet, delayed release, Tablet, delayed release - Oral, Capsule, Capsule - Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, Tablet - Oral, Tablet, coated, Tablet, coated - Oral, Capsule, gelatin coated, Capsule, gelatin coated - Oral, Capsule, delayed release pellets, Capsule, delayed release pellets - Oral, Kit - Oral, Kit, Capsule, extended release, Capsule, extended release - Oral, Powder - Intravenous, Powder, for suspension, Powder, for suspension - Oral, Syrup - Oral, Syrup, For suspension - Oral, Gel - Oral, Suspension - Oral, Capsule, Delayed Release - Oral, Capsule, Delayed Release, Powder, For suspension, Oral; Topical, Capsule - Oral; Topical, Injection, powder, for solution, Injection, powder, for solution - Intravenous
Rickettsialpox
10.0 mg/mL, , 75.0 mg, 100.0 mg, 150.0 mg, 50.0 mg, 200.0 mg, 20.0 mg, 1.0 mg/mg, 40.0 mg, 5.0 mg/mg, 7.5 mg/mg, 25.0 mg/mL, 50.0 mg/mL, 120.0 mg, 60.0 mg, 0.1 mg/mg, 5.0 mg/mL, 8.8 %, 20.0 mg/mL, 0.75 mg/mg, 0.5 mg/mg, 80.0 mg
, Intravenous, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous, Oral, Tablet, delayed release, Tablet, delayed release - Oral, Capsule, Capsule - Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, Tablet - Oral, Tablet, coated, Tablet, coated - Oral, Capsule, gelatin coated, Capsule, gelatin coated - Oral, Capsule, delayed release pellets, Capsule, delayed release pellets - Oral, Kit - Oral, Kit, Capsule, extended release, Capsule, extended release - Oral, Powder - Intravenous, Powder, for suspension, Powder, for suspension - Oral, Syrup - Oral, Syrup, For suspension - Oral, Gel - Oral, Suspension - Oral, Capsule, Delayed Release - Oral, Capsule, Delayed Release, Powder, For suspension, Oral; Topical, Capsule - Oral; Topical, Injection, powder, for solution, Injection, powder, for solution - Intravenous
Plague
10.0 mg/mL, , 75.0 mg, 100.0 mg, 150.0 mg, 50.0 mg, 200.0 mg, 20.0 mg, 1.0 mg/mg, 40.0 mg, 5.0 mg/mg, 7.5 mg/mg, 25.0 mg/mL, 50.0 mg/mL, 120.0 mg, 60.0 mg, 0.1 mg/mg, 5.0 mg/mL, 8.8 %, 20.0 mg/mL, 0.75 mg/mg, 0.5 mg/mg, 80.0 mg
, Intravenous, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous, Oral, Tablet, delayed release, Tablet, delayed release - Oral, Capsule, Capsule - Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, Tablet - Oral, Tablet, coated, Tablet, coated - Oral, Capsule, gelatin coated, Capsule, gelatin coated - Oral, Capsule, delayed release pellets, Capsule, delayed release pellets - Oral, Kit - Oral, Kit, Capsule, extended release, Capsule, extended release - Oral, Powder - Intravenous, Powder, for suspension, Powder, for suspension - Oral, Syrup - Oral, Syrup, For suspension - Oral, Gel - Oral, Suspension - Oral, Capsule, Delayed Release - Oral, Capsule, Delayed Release, Powder, For suspension, Oral; Topical, Capsule - Oral; Topical, Injection, powder, for solution, Injection, powder, for solution - Intravenous
Chancroid
10.0 mg/mL, , 75.0 mg, 100.0 mg, 150.0 mg, 50.0 mg, 200.0 mg, 20.0 mg, 1.0 mg/mg, 40.0 mg, 5.0 mg/mg, 7.5 mg/mg, 25.0 mg/mL, 50.0 mg/mL, 120.0 mg, 60.0 mg, 0.1 mg/mg, 5.0 mg/mL, 8.8 %, 20.0 mg/mL, 0.75 mg/mg, 0.5 mg/mg, 80.0 mg
, Intravenous, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous, Oral, Tablet, delayed release, Tablet, delayed release - Oral, Capsule, Capsule - Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, Tablet - Oral, Tablet, coated, Tablet, coated - Oral, Capsule, gelatin coated, Capsule, gelatin coated - Oral, Capsule, delayed release pellets, Capsule, delayed release pellets - Oral, Kit - Oral, Kit, Capsule, extended release, Capsule, extended release - Oral, Powder - Intravenous, Powder, for suspension, Powder, for suspension - Oral, Syrup - Oral, Syrup, For suspension - Oral, Gel - Oral, Suspension - Oral, Capsule, Delayed Release - Oral, Capsule, Delayed Release, Powder, For suspension, Oral; Topical, Capsule - Oral; Topical, Injection, powder, for solution, Injection, powder, for solution - Intravenous
Mycoplasma Pneumoniae
10.0 mg/mL, , 75.0 mg, 100.0 mg, 150.0 mg, 50.0 mg, 200.0 mg, 20.0 mg, 1.0 mg/mg, 40.0 mg, 5.0 mg/mg, 7.5 mg/mg, 25.0 mg/mL, 50.0 mg/mL, 120.0 mg, 60.0 mg, 0.1 mg/mg, 5.0 mg/mL, 8.8 %, 20.0 mg/mL, 0.75 mg/mg, 0.5 mg/mg, 80.0 mg
, Intravenous, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous, Oral, Tablet, delayed release, Tablet, delayed release - Oral, Capsule, Capsule - Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, Tablet - Oral, Tablet, coated, Tablet, coated - Oral, Capsule, gelatin coated, Capsule, gelatin coated - Oral, Capsule, delayed release pellets, Capsule, delayed release pellets - Oral, Kit - Oral, Kit, Capsule, extended release, Capsule, extended release - Oral, Powder - Intravenous, Powder, for suspension, Powder, for suspension - Oral, Syrup - Oral, Syrup, For suspension - Oral, Gel - Oral, Suspension - Oral, Capsule, Delayed Release - Oral, Capsule, Delayed Release, Powder, For suspension, Oral; Topical, Capsule - Oral; Topical, Injection, powder, for solution, Injection, powder, for solution - Intravenous
Urinary Tract Infections
10.0 mg/mL, , 75.0 mg, 100.0 mg, 150.0 mg, 50.0 mg, 200.0 mg, 20.0 mg, 1.0 mg/mg, 40.0 mg, 5.0 mg/mg, 7.5 mg/mg, 25.0 mg/mL, 50.0 mg/mL, 120.0 mg, 60.0 mg, 0.1 mg/mg, 5.0 mg/mL, 8.8 %, 20.0 mg/mL, 0.75 mg/mg, 0.5 mg/mg, 80.0 mg
, Intravenous, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous, Oral, Tablet, delayed release, Tablet, delayed release - Oral, Capsule, Capsule - Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, Tablet - Oral, Tablet, coated, Tablet, coated - Oral, Capsule, gelatin coated, Capsule, gelatin coated - Oral, Capsule, delayed release pellets, Capsule, delayed release pellets - Oral, Kit - Oral, Kit, Capsule, extended release, Capsule, extended release - Oral, Powder - Intravenous, Powder, for suspension, Powder, for suspension - Oral, Syrup - Oral, Syrup, For suspension - Oral, Gel - Oral, Suspension - Oral, Capsule, Delayed Release - Oral, Capsule, Delayed Release, Powder, For suspension, Oral; Topical, Capsule - Oral; Topical, Injection, powder, for solution, Injection, powder, for solution - Intravenous
Necrotizing ulcerative gingivostomatitis
10.0 mg/mL, , 75.0 mg, 100.0 mg, 150.0 mg, 50.0 mg, 200.0 mg, 20.0 mg, 1.0 mg/mg, 40.0 mg, 5.0 mg/mg, 7.5 mg/mg, 25.0 mg/mL, 50.0 mg/mL, 120.0 mg, 60.0 mg, 0.1 mg/mg, 5.0 mg/mL, 8.8 %, 20.0 mg/mL, 0.75 mg/mg, 0.5 mg/mg, 80.0 mg
, Intravenous, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous, Oral, Tablet, delayed release, Tablet, delayed release - Oral, Capsule, Capsule - Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, Tablet - Oral, Tablet, coated, Tablet, coated - Oral, Capsule, gelatin coated, Capsule, gelatin coated - Oral, Capsule, delayed release pellets, Capsule, delayed release pellets - Oral, Kit - Oral, Kit, Capsule, extended release, Capsule, extended release - Oral, Powder - Intravenous, Powder, for suspension, Powder, for suspension - Oral, Syrup - Oral, Syrup, For suspension - Oral, Gel - Oral, Suspension - Oral, Capsule, Delayed Release - Oral, Capsule, Delayed Release, Powder, For suspension, Oral; Topical, Capsule - Oral; Topical, Injection, powder, for solution, Injection, powder, for solution - Intravenous
Dysentery, Bacillary
10.0 mg/mL, , 75.0 mg, 100.0 mg, 150.0 mg, 50.0 mg, 200.0 mg, 20.0 mg, 1.0 mg/mg, 40.0 mg, 5.0 mg/mg, 7.5 mg/mg, 25.0 mg/mL, 50.0 mg/mL, 120.0 mg, 60.0 mg, 0.1 mg/mg, 5.0 mg/mL, 8.8 %, 20.0 mg/mL, 0.75 mg/mg, 0.5 mg/mg, 80.0 mg
, Intravenous, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous, Oral, Tablet, delayed release, Tablet, delayed release - Oral, Capsule, Capsule - Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, Tablet - Oral, Tablet, coated, Tablet, coated - Oral, Capsule, gelatin coated, Capsule, gelatin coated - Oral, Capsule, delayed release pellets, Capsule, delayed release pellets - Oral, Kit - Oral, Kit, Capsule, extended release, Capsule, extended release - Oral, Powder - Intravenous, Powder, for suspension, Powder, for suspension - Oral, Syrup - Oral, Syrup, For suspension - Oral, Gel - Oral, Suspension - Oral, Capsule, Delayed Release - Oral, Capsule, Delayed Release, Powder, For suspension, Oral; Topical, Capsule - Oral; Topical, Injection, powder, for solution, Injection, powder, for solution - Intravenous
Clostridium difficile Infection
10.0 mg/mL, , 75.0 mg, 100.0 mg, 150.0 mg, 50.0 mg, 200.0 mg, 20.0 mg, 1.0 mg/mg, 40.0 mg, 5.0 mg/mg, 7.5 mg/mg, 25.0 mg/mL, 50.0 mg/mL, 120.0 mg, 60.0 mg, 0.1 mg/mg, 5.0 mg/mL, 8.8 %, 20.0 mg/mL, 0.75 mg/mg, 0.5 mg/mg, 80.0 mg
, Intravenous, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous, Oral, Tablet, delayed release, Tablet, delayed release - Oral, Capsule, Capsule - Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, Tablet - Oral, Tablet, coated, Tablet, coated - Oral, Capsule, gelatin coated, Capsule, gelatin coated - Oral, Capsule, delayed release pellets, Capsule, delayed release pellets - Oral, Kit - Oral, Kit, Capsule, extended release, Capsule, extended release - Oral, Powder - Intravenous, Powder, for suspension, Powder, for suspension - Oral, Syrup - Oral, Syrup, For suspension - Oral, Gel - Oral, Suspension - Oral, Capsule, Delayed Release - Oral, Capsule, Delayed Release, Powder, For suspension, Oral; Topical, Capsule - Oral; Topical, Injection, powder, for solution, Injection, powder, for solution - Intravenous
Klebsiella Infections
10.0 mg/mL, , 75.0 mg, 100.0 mg, 150.0 mg, 50.0 mg, 200.0 mg, 20.0 mg, 1.0 mg/mg, 40.0 mg, 5.0 mg/mg, 7.5 mg/mg, 25.0 mg/mL, 50.0 mg/mL, 120.0 mg, 60.0 mg, 0.1 mg/mg, 5.0 mg/mL, 8.8 %, 20.0 mg/mL, 0.75 mg/mg, 0.5 mg/mg, 80.0 mg
, Intravenous, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous, Oral, Tablet, delayed release, Tablet, delayed release - Oral, Capsule, Capsule - Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, Tablet - Oral, Tablet, coated, Tablet, coated - Oral, Capsule, gelatin coated, Capsule, gelatin coated - Oral, Capsule, delayed release pellets, Capsule, delayed release pellets - Oral, Kit - Oral, Kit, Capsule, extended release, Capsule, extended release - Oral, Powder - Intravenous, Powder, for suspension, Powder, for suspension - Oral, Syrup - Oral, Syrup, For suspension - Oral, Gel - Oral, Suspension - Oral, Capsule, Delayed Release - Oral, Capsule, Delayed Release, Powder, For suspension, Oral; Topical, Capsule - Oral; Topical, Injection, powder, for solution, Injection, powder, for solution - Intravenous

Warnings

Periostat has three contraindications and should not be ingested when any of the conditions mentioned in the table below are present.Periostat Contraindications
Condition
Risk Level
Notes
Severe Hypersensitivity Reactions
Do Not Combine
Doxycycline may interact with Pulse Frequency
Pulse Frequency
Do Not Combine
Severe Hypersensitivity Reactions
Do Not Combine
Doxycycline may interact with Pulse Frequency
There are 20 known major drug interactions with Periostat.
Common Periostat Drug Interactions
Drug Name
Risk Level
Description
Abemaciclib
Major
The metabolism of Abemaciclib can be decreased when combined with Doxycycline.
Acalabrutinib
Major
The metabolism of Acalabrutinib can be decreased when combined with Doxycycline.
Alectinib
Major
The metabolism of Alectinib can be decreased when combined with Doxycycline.
Alpelisib
Major
The metabolism of Alpelisib can be decreased when combined with Doxycycline.
Amdinocillin
Major
The therapeutic efficacy of Amdinocillin can be decreased when used in combination with Doxycycline.
Periostat Toxicity & Overdose RiskThe toxic dose of doxycycline in rats is 2000mg/kg, 1870mg/kg in mice, and 500mg/kg in dogs. If an overdose happens, doxycycline should be stopped and supportive medical care should be given. Dialysis will not reduce the amount of the drug in the body and is not recommended for overdoses.
image of a doctor in a lab doing drug, clinical research

Periostat Novel Uses: Which Conditions Have a Clinical Trial Featuring Periostat?

34 ongoing studies are examining the potential of Periostat to combat Haemophilus Influenzae Infections, Respiratory Tract Infections and Amebic Colitis.
Condition
Clinical Trials
Trial Phases
Plague
0 Actively Recruiting
Plague
0 Actively Recruiting
Epididymo-orchitis gonococcal
0 Actively Recruiting
Lymphogranuloma Venereum
0 Actively Recruiting
Gonorrhea
0 Actively Recruiting
Urinary Tract Infections
7 Actively Recruiting
Not Applicable, Phase 4
Chlamydia trachomatis
0 Actively Recruiting
Pneumococcal Infections
0 Actively Recruiting
Urethritis
0 Actively Recruiting
Typhus, Endemic Flea-Borne
0 Actively Recruiting
Clostridium difficile Infection
0 Actively Recruiting
Communicable Diseases
0 Actively Recruiting
Chlamydia Infections
0 Actively Recruiting
inhaled anthrax caused by Bacillus anthracis
0 Actively Recruiting
Calymmatobacterium granulomatis
0 Actively Recruiting
Haemophilus Influenzae Infections
0 Actively Recruiting
Chancroid
0 Actively Recruiting
Klebsiella Infections
0 Actively Recruiting
Rosacea
2 Actively Recruiting
Early Phase 1, Phase 2
Rocky Mountain Spotted Fever
0 Actively Recruiting

Periostat Reviews: What are patients saying about Periostat?

5Patient Review
2/8/2010
Periostat for Inflammation of the Gums and Mouth
I am a smoker with moderate to advanced periodontal disease. My periodontist performed scaling and root planning with localized surgical treatment. After several years in maintenance my condition began to breakdown. I began using periostat and slowly over the next nine months the periodontist noted a decrease in my bleeding and inflammation as well as my pocket depths. This medication has worked from inside my body to help control the inflammation response to my periodontal infection.
2.3Patient Review
3/10/2010
Periostat for Inflammation of the Gums and Mouth
Since having a hysterectomy (not related to periostat), I've been having some serious digestive issues. Bloating, gas, indigestion; the works. I'm currently taking glutamine and probiotics, but I'm not sure if it's the medicine or not. I was on it for years before this happened, and the package did have warnings about long term use.
1Patient Review
10/24/2008
Periostat for Additional Medication for Inflammation Around the Teeth
After having some dental work done, my dentist prescribed this medication. However, I had to stop taking it because it resulted in blood in my stool. I also had to stop taking other medications (simvastatin, baby aspirin and Chantix) until the condition clears up.
image of drug pills surrounding a glass of water symbolizing drug consumption

Patient Q&A Section about periostat

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

How long should you use Periostat?

"PERIOSTAT is meant to be used for treatment periods of 3 months. It shouldn't be used for more than 3 consecutive three-month periods. There's no need to change the dosage for elderly patients."

Answered by AI

Is Periostat the same as doxycycline?

"Periostat is a drug used to help reduce pocket depth and promote attachment level gain in patients with adult periodontitis. The dosage of Periostat is different from that of doxycycline, which is used to treat infections."

Answered by AI

What is Periostat used for?

"Periostat is used to treat periodontitis, a condition that affects the gums and can cause teeth to become loose or fall out. The standard treatment for periodontitis is scaling and root planing, which is done by a dentist or dental hygienist."

Answered by AI

What is Periostat periodontics?

"Periostat is an orally administered tablet that contains a novel formulation of 23.08mg doxycycline hyclate. It is designed to be taken twice a day as an adjunct to scaling and root planing (SRP), and has been shown to increase clinical attachment level gain and reduce probing depths in patients with chronic periodontitis."

Answered by AI

Clinical Trials for Periostat

Image of Baylor College of Medicine in Houston, United States.

Educational Tool for Urinary Tract Infections

18+
All Sexes
Houston, TX
Urine culture is the most common microbiological test in the outpatient setting in the United States. Unfortunately, contamination during collection is prevalent and undermines test accuracy, leading to incorrect diagnosis, unnecessary treatment, wasted laboratory resources, and inflated costs. Unnecessary antibiotic treatment increases the risk of developing antimicrobial resistance, one of the most serious threats to patients and public health. The goal of this clinical trial is to test whether a bilingual (English and Spanish) educational intervention, an animated video and pictorial flyer, can reduce urine culture contamination and associated inappropriate antibiotic use in adult patients visiting safety-net primary care clinics. The main questions it aims to answer are: 1. Does providing patients with a bilingual educational intervention reduce urine culture contamination rates? 2. Does the intervention lead to fewer unnecessary urinary antibiotic prescriptions? 3. Does providing patients with a bilingual educational intervention reduce contaminated urinalyses? Researchers will compare patients randomized to receive the educational intervention (video and flyer) to those receiving usual care to see if the intervention improves urine collection accuracy and reduces inappropriate antibiotic use. Participants will watch a short, animated video with step-by-step instructions for proper midstream clean-catch urine (MSCC) collection, receive a pictorial flyer (with stills from the video) reinforcing the instructions, and provide a urine sample for culture. For our hypothesis, patients who receive the educational intervention will have: lower urine culture contamination rates (primary outcome), fewer urinary antibiotic prescriptions (secondary outcome), and fewer contaminated urinalyses (secondary outcome). The objectives are to (1) develop educational tools: Create an animated video and pictorial flyer with step-by-step urine collection instructions for women and men, developed through an iterative, stakeholder-engaged process, (2) assess acceptability: Use mixed methods (quantitative surveys and qualitative interviews) to evaluate and refine the tools for usability and cultural/linguistic appropriateness, and (3) test effectiveness: Conduct a randomized controlled trial to assess the intervention's impact on urine contamination rates, antibiotic prescribing, and patient satisfaction.
Waitlist Available
Has No Placebo
Baylor College of MedicineLarissa Grigoryan, MD, PhD
Image of UPMC Magee-Womens Hospital in Pittsburgh, United States.

Catheterization Methods for Postpartum Urinary Problems

18+
All Sexes
Pittsburgh, PA
At least ten percent of patients have postpartum urinary retention or difficulty urinating after birth, which can cause incontinence and other urinary problems long-term. After getting an epidural placed, patients should be numb in their pelvic region. This numbness makes it difficult to feel the need to urinate, so patients need a urinary catheter placed to empty the bladder. Some patients have one catheter placed throughout their labor and others have a catheter placed to empty the bladder then removed every few hours. The investigators are studying whether placing a catheter once or catheterizing multiple times affects the rate of postpartum urinary problems and infection.
Waitlist Available
Has No Placebo
UPMC Magee-Womens HospitalAnna Binstock, MD
Image of University of California, San Francisco in San Francisco, United States.

Trimethoprim-Sulfamethoxazole for Urinary Tract Infections

13 - 29
All Sexes
San Francisco, CA
The goal of this clinical trial is to learn if a common antibiotic called trimethoprim-sulfamethoxazole (TMP-SMX) can help prevent urinary tract infections (UTIs) in children and young adults who recently had a kidney transplant. Most people take TMP-SMX for about 6 months after getting a kidney transplant. In this study, researchers want to see what happens if people keep taking it for 6 more months. The main questions this study is asking are: * Does TMP-SMX lower the number of UTIs in the first year after transplant? * What side effects or problems do participants have while taking TMP-SMX? Researchers will compare TMP-SMX to a placebo (a look-alike pill that does not contain any medication) to see if TMP-SMX works to prevent UTIs. Participants will: * Take either TMP-SMX or a placebo pill by mouth every day for 6 months * Have three visits to touch base with the study team about any issues * Complete short monthly online surveys about any symptoms or side effects * Share blood and urine test results from their regular transplant clinic visits
Phase 4
Waitlist Available
University of California, San FranciscoAlexandra Bicki, MD
Have you considered Periostat clinical trials? We made a collection of clinical trials featuring Periostat, we think they might fit your search criteria.Go to Trials
Image of Children's Community Pediatrics Brentwood in Pittsburgh, United States.

AI Diagnostic Support for Ear Infections

6 - 24
All Sexes
Pittsburgh, PA
Ear infections are common in young children with cold symptoms, but they can be difficult to diagnose due to small ear canals, child movement, and limited viewing time. In this study, investigators will take photos of the eardrums of children 6-24 months of age with upper respiratory symptoms. The photos will be reviewed by imaging software enhanced with artificial intelligence (AI app) to determine whether the AI app changes how ear infections are diagnosed and treated. The AI app has undergone rigorous study and was found to be highly accurate; but how using this technology affects the diagnosis and treatment by clinicians has not been studied. This research may help improve diagnostic accuracy for ear infections and ensure antibiotics are prescribed only for those children who have definite ear infections.
Waitlist Available
Has No Placebo
Children's Community Pediatrics Brentwood (+1 Sites)Timothy R Shope, MD, MPHMerck Sharp & Dohme LLC
Image of Atlantic Health in Morristown, United States.

Methenamine for Urinary Tract Infection

18 - 100
Female
Morristown, NJ
Stress urinary incontinence (SUI) affects at least 40% of women in the United States. Synthetic polypropylene mid-urethral slings (MUS) are the gold standard treatment for SUI. Post-operative urinary tract infections (UTI) are one of the most common complications after MUS placement. Some studies have demonstrated that MUS placement can increase the risk of UTI up to 21-34%. Post-operative UTI can lead to significant healthcare and patient burden. This additional burden further contributes to an estimated annual cost of $1.6 billion for UTI management in the United States. With increased antibiotic usage, there is simultaneous increase in bacterial resistance leading to treatment refractory UTI. The investigators prescribe post-operative antibiotics prophylactically for 3 days after MUS placement with or without concurrent pelvic reconstructive surgery based on prior literature recommending post-operative prophylaxis. There is a greater emphasis on limiting antibiotic use given the trend of development of bacterial resistance. There are studies supporting alternatives such as methenamine for recurrent UTI prophylaxis treatment, but there are limited studies evaluating methenamine for UTI prophylaxis after MUS.
Recruiting
Has No Placebo
Atlantic Health
Image of University of Pennsylvania Primary Care Practice in Philadelphia, United States.

Rapid Testing for Upper Respiratory Tract Infection

18+
All Sexes
Philadelphia, PA
The goal of this study is to understand the use of point of care (POC) testing devices in primary care offices to help clinicians diagnose and appropriately treat patients who have symptoms of upper respiratory infections (URIs). The study will use the BIOFIRE® SPOTFIRE® Respiratory (R) Panel testing device, which is FDA-cleared and CLIA-Waived. This panel can identify up to 15 different viruses and bacteria that can cause URIs. These POC devices will be installed in primary care clinics within the University of Pennsylvania Health System. Patients who come to the clinic with cold-like symptoms (runny nose, cough) will be offered the test. If the patient agrees to the test, their clinician will use a swab to take a small sample of fluid from their nose. This swab will then be tested within the POC device and results will be available within 15 minutes. The results of this sample will be shared with the patient, and their clinician can use the results to help decide the most appropriate medical treatment for the patient. Patients who agree to take the test will be asked to answer a short survey about the test and their experience. Clinicians will also be surveyed to share their thoughts with using the test in their clinics. Focus groups of practice staff and clinicians will also be conducted to understand any potential challenges for using this test in practice. Results from the tests and the surveys will help researchers understand the value of the test to support antibiotic stewardship efforts in primary care clinic settings.
Waitlist Available
Has No Placebo
University of Pennsylvania Primary Care Practice
Have you considered Periostat clinical trials? We made a collection of clinical trials featuring Periostat, we think they might fit your search criteria.Go to Trials
Image of George Washington University Hospital in Washington, United States.

Rapid Test for Respiratory Infections

18+
All Sexes
Washington, United States
The study titled " The Effect of Definitive Identification of Viral Etiology in Emergency Department Patients with Acute Respiratory Infection on Antibiotic Utilization (RADIATE)" aims to investigate the effectiveness of a rapid diagnostic approach in reducing unnecessary antibiotic use in the emergency department (ED) for patients presenting with acute respiratory illness (ARI) due to a virus. Using a prospective design, eligible participants are individuals who visit the ED with complaints related to acute respiratory illness. The study will employ a single-arm consecutive enrollment approach. The intervention involves the implementation of a rapid point-of-care multiplex polymerase chain reaction (PCR) test to promptly identify the viral cause of the infection. By utilizing a rapid diagnostic tool to identify viral etiology, the study aims to provide healthcare professionals in the ED with more accurate information to guide treatment decisions. Ultimately, the goal is to decrease the unnecessary use of antibiotics for ARI's due to a virus, which has several negative outcomes including promotion of antibiotic resistance, exacerbating ED length of stay and encouraging unnecessary additional diagnostic tests.
Waitlist Available
Has No Placebo
George Washington University Hospital (+2 Sites)Christopher Payette, MDBioMérieux
Have you considered Periostat clinical trials? We made a collection of clinical trials featuring Periostat, we think they might fit your search criteria.Go to Trials
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Terms of Service·Privacy Policy·Cookies·Security